This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/521719-india-covaxin-vaccine-covid19-trial/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| India’s indigenously developed Covaxin jab 78% effective against Covid-19 in trials, maker Bharat Biotech says | India’s indigenously developed Covaxin jab 78% effective against Covid-19 in trials, maker Bharat Biotech says |
| (4 months later) | |
| The Covid-19 vaccine developed by Indian pharmaceutical firm Bharat Biotech has been found to be 78% effective in preventing symptoms of Covid-19 and 100% against severe disease in stage three trials, the company said. | The Covid-19 vaccine developed by Indian pharmaceutical firm Bharat Biotech has been found to be 78% effective in preventing symptoms of Covid-19 and 100% against severe disease in stage three trials, the company said. |
| In a press release on Wednesday, Bharat Biotech published second-round interim results from stage-three trials of the country’s first indigenous Covid-19 jab. The data, which was based on a trial of more than 25,000 participants, showed the formulation to have 78% efficacy in preventing symptomatic Covid-19 – and totally effective in preventing severe forms of the disease. | In a press release on Wednesday, Bharat Biotech published second-round interim results from stage-three trials of the country’s first indigenous Covid-19 jab. The data, which was based on a trial of more than 25,000 participants, showed the formulation to have 78% efficacy in preventing symptomatic Covid-19 – and totally effective in preventing severe forms of the disease. |
| "The efficacy data against severe Covid-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively,” the company’s boss, Krishna Ella, said in a statement. | "The efficacy data against severe Covid-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively,” the company’s boss, Krishna Ella, said in a statement. |
| Balram Bhargava, secretary of health research & director general of the Indian Council of Medical Research, praised the hard work of the scientists involved and said he was pleased by the jab’s protection against new virus variants. | Balram Bhargava, secretary of health research & director general of the Indian Council of Medical Research, praised the hard work of the scientists involved and said he was pleased by the jab’s protection against new virus variants. |
| “I am also happy to note that Covaxin works well against most variants of SARS-CoV-2. These findings together consolidate the position of our indigenous vaccine in the global vaccine landscape,” he stated. | “I am also happy to note that Covaxin works well against most variants of SARS-CoV-2. These findings together consolidate the position of our indigenous vaccine in the global vaccine landscape,” he stated. |
| The vaccine has been administered several million times in India and has been given emergency approval in a number of other countries, including Iran, which granted a permit for its use in February, long before reflective trial results were available. Interim analysis from March 1 suggested the jab was 81% effective. | The vaccine has been administered several million times in India and has been given emergency approval in a number of other countries, including Iran, which granted a permit for its use in February, long before reflective trial results were available. Interim analysis from March 1 suggested the jab was 81% effective. |
| According to Bharat Biotech, more than 60 countries have expressed interest in purchasing the jab. Last week, India’s Ministry of Science & Technology said it was aiming at manufacturing 100 million doses every month by September, up from 10 million in April. | According to Bharat Biotech, more than 60 countries have expressed interest in purchasing the jab. Last week, India’s Ministry of Science & Technology said it was aiming at manufacturing 100 million doses every month by September, up from 10 million in April. |
| India is one of the world’s largest Covid-19 manufacturers, but has recently banned exports in an effort to prioritize the vaccination of its citizens amid a worrying increase in cases. The country’s latest mutant strain has also become an issue, with two major mutations potentially making it more resistant to vaccines and a ‘variant of concern’ across the world. | India is one of the world’s largest Covid-19 manufacturers, but has recently banned exports in an effort to prioritize the vaccination of its citizens amid a worrying increase in cases. The country’s latest mutant strain has also become an issue, with two major mutations potentially making it more resistant to vaccines and a ‘variant of concern’ across the world. |
| If you like this story, share it with a friend! | If you like this story, share it with a friend! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |